Gilead Sciences (GILD) Tops Q4 EPS by 19c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Revenue Growth %: -0.4%
Financial Fact:
Interest and other income, net: 119M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.90, $0.19 better than the analyst estimate of $1.71. Revenue for the quarter came in at $7.6 billion versus the consensus estimate of $7.16 billion.
GUIDANCE:
Gilead Sciences sees FY2025 EPS of $7.70-$8.10, versus the consensus of $7.54. Gilead Sciences sees FY2025 revenue of $28.2-28.6 billion, versus the consensus of $28 billion.
For the full-year 2025, Gilead expects:
(in millions, except per share amounts) |
| February 11, 2025 Guidance | |||||
| Low End |
| High End | ||||
Product sales |
| $ | 28,200 |
| $ | 28,600 | |
Product sales excluding Veklury |
| $ | 26,800 |
| $ | 27,200 | |
Veklury |
| $ | 1,400 |
| $ | 1,400 | |
Diluted EPS |
| $ | 5.95 |
| $ | 6.35 | |
Non-GAAP diluted EPS |
| $ | 7.70 |
| $ | 8.10 | |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- APA Corporation releases Q3 2026 preliminary financial data
- Gilead Sciences (GILD) PT Lowered to $163 at Morgan Stanley
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
